Abstract
Genes from the RAF family are Ras-regulated kinases involved in growth cellular responses. Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR). Additionally, BRAF mutations were described only in K-Ras-negative colon carcinomas, suggesting that BRAF/K-Ras activating mutations might be alternative genetic events in colon cancer. We have addressed to what extent the tumorigenic-positive selection exerted by BRAF mutations seen in colorectal MMR-deficient tumors was also involved in the tumorigenesis of gastric cancer. Accordingly, BRAF mutations were detected in 34% (25/74) of colorectal MMR-deficient tumors and in 5% (7/142) of MMR-proficient colorectal cases (P=0.0001). All mutations found in the MSI cases corresponded to the previously reported hotspot V599E. Two D593K and a K600E additional mutations were also detected in three MSS cases. However, only one mutation of BRAF was found within 124 MSS gastric tumors and none in 37 MSI gastric tumors, clearly suggesting that BRAF mutations are not involved in gastric tumorigenesis. Nonetheless, a high incidence of mutations of K-Ras was found within the MSI gastric group of tumors (P=0.0005), suggesting that the activation of K-Ras-dependent pathways contributes to the tumorigenesis of gastric cancers with MMR deficiency. Accordingly, our results show evidences that BRAF mutations characterize colon but not gastric tumors with MMR deficiency and are not involved in the tumorigenesis of gastric cancer of the mutator phenotype pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B and de la Chapelle A . (1993). Science, 260, 812–816.
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodrigues-Bigas MA, Fodde R, Ranzani GN and Srivastava S . (1998). Cancer Res., 58, 5248–5257.
Brennetot C, Pinto M, Oliveira C, Schwartz Jr S, Seruca R, Duval A and Hamelin R : Gastroenterology. (in press).
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.
Duval A and Hamelin R . (2002). Cancer Res., 62, 2447–2454.
Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P and Hamelin R . (2001). Oncogene, 20, 5025–5032.
Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G and Hamelin R . (1997). Cancer Res., 57, 300–303.
Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M . (1993). Nature, 363, 558–561.
Oliveira C, Seruca R, Seixas M and Sobrinho-Simões M . (1998). Am. J. Pathol., 153, 1211–1219.
Perucho M . (1996). J. Biol. Chem., 377, 675–684.
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE . (2002). Nature, 418, 934.
Schwartz Jr S, Yamamoto H, Navarro M, Maestro M, Reventós J and Perucho M . (1999). Cancer Res., 59, 2995–3002.
Thibodeau SN, Bren G and Schaid D . (1993). Science, 260, 816–819.
Yamamoto H, Fukushima H, Itoh F, Horiuchi S, Min Y, Iku S and Imai K . (2001). J. Exp. Clin. Cancer Res., 20, 553–559.
Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K and Perucho M . (1999). Gastroenterology, 116, 1348–1357.
Yamamoto H, Sawai H and Perucho M . (1997). Cancer Res., 57, 4420–4426.
Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.
Acknowledgements
This work was supported by Grant FIS 01/1350 from the Spanish Fondo de Investigaciones Sanitarias and Fundação para a Ciência e a Tecnologia, Portugal (Project: POCTI/35374/CBO/2000 and POCTI/CBO/40820/2001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oliveira, C., Pinto, M., Duval, A. et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22, 9192–9196 (2003). https://doi.org/10.1038/sj.onc.1207061
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207061
Keywords
This article is cited by
-
Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives
Drugs (2019)
-
KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status
Pathology & Oncology Research (2019)
-
Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer
BMC Cancer (2016)
-
Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer
World Journal of Microbiology and Biotechnology (2016)
-
Opportunities for immunotherapy in microsatellite instable colorectal cancer
Cancer Immunology, Immunotherapy (2016)